12:00 AM
 | 
Feb 07, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

NN9161: Development discontinued

Novo Nordisk disclosed in its 4Q10 earnings that it discontinued development of NN9161 due to an...

Read the full 57 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >